|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C29H28N6O2 |
|||
| Molecular Weight | 492.57 | CAS No. | 1100598-32-0 | |
| Solubility (25°C)* | In vitro | DMSO | 5 mg/mL (10.15 mM) | |
| Ethanol | 1 mg/mL (2.03 mM) | |||
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Tepotinib is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib (EMD 1214063) induces autophagy. Phase 1. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro | EMD 1214063 inhibits HGF-induced c-Met phosphorylation in A549 cells with IC50 of 6 nM. Treatment with EMD 1214063 induces a marked reduction of c-Met–constitutive phosphorylation in EBC-1 cells with IC50 of 9 nM. EMD 1214063 effectively blocka phosphorylation of the major downstream effectors of the c-Met enzyme, such as Grb2, Gab1, Sos, PLCγ, and phosphoinositide 3-kinase, in EBC-1, MKN-45, and Hs746T cells in the range of 1 to 10 nM. EMD 1214063 considerably inhibits the viability of MKN-45 cells with IC50 of less than 1 nM. Treatment with EMD 1214063 (as low as 0.1 nM) inhibits HGF-induced NCI-H441 cell migration, whereas concentrations of 100 nM to 1 μM almost completely prevents it. [1] | ||
| In vivo | EMD 1214063 treatment, at doses of 10 mg/kg or more, results in more than 90% inhibition of c-Met phosphorylation in Hs746T xenograft tumor for a period of at least 72 hours. EMD 1214063 induces more than 50% reduction of cyclin D1 expression, which persists after 96 hours upon treatment with doses of 100 mg/kg. A transient induction of p27 and cleaved caspase-3 are also observed upon treatment with EMD 1214063. EMD 1214063 (15 mg/kg, daily) treatment induces complete regression of gastric carcinoma xenografts Hs746T, in which c-Met is amplified, overexpressed, and activated in a ligand-independent fashion. [1] |
Protocol (from reference)
| Animal Study: |
|
|---|
Customer Product Validation
-S706701Z0220150917.gif)
-
Data from [Data independently produced by , , Cell Research, 2015, 25: 445-458]
-
Data from [Data independently produced by , , Biochim Biophys Acta Mol Basis Dis, 2018, 1864(3):793-803]
-
Data from [Data independently produced by , , J Virol, 2016, 90(14):6412-29. ]
Selleck's Tepotinib has been cited by 18 publications
| TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer [ Oncogene, 2024, 10.1038/s41388-024-02987-5] | PubMed: 38485737 |
| Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the MET Gene: Doublet Treatment versus Single Agent Treatment [ Int J Mol Sci, 2024, 25(3)1769] | PubMed: 38339049 |
| Bladder cancer organoids as a functional system to model different disease stages and therapy response [ Nat Commun, 2023, 14(1):2214] | PubMed: 37072390 |
| "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction" [ J Exp Clin Cancer Res, 2023, 42(1):8] | PubMed: 36604765 |
| Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR [ J Exp Clin Cancer Res, 2023, 10.1186/s13046-023-02866-z] | PubMed: 37924112 |
| Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer [ Cancer Sci, 2023, 10.1111/cas.15958] | PubMed: 37715310 |
| Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44 [ Cancers (Basel), 2022, 14(14)3444] | PubMed: 35884507 |
| MET∆14 promotes a ligand-dependent, AKT-driven invasive growth [ Life Sci Alliance, 2022, 5(10)e202201409] | PubMed: 35636967 |
| The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells [ Int J Mol Sci, 2020, 21(21)E7905] | PubMed: 33114380 |
| SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer [ Transl Lung Cancer Res, 2020, 9(5):1810-1821] | PubMed: 33209603 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.